

Antineoplastic Drugs-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/AB9FF12E635MEN.html>

Date: May 2018

Pages: 159

Price: US\$ 3,480.00 (Single User License)

ID: AB9FF12E635MEN

Abstracts

Report Summary

Antineoplastic Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Antineoplastic Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Antineoplastic Drugs 2013-2017, and development forecast 2018-2023

Main market players of Antineoplastic Drugs in United States, with company and product introduction, position in the Antineoplastic Drugs market

Market status and development trend of Antineoplastic Drugs by types and applications

Cost and profit status of Antineoplastic Drugs, and marketing status

Market growth drivers and challenges

The report segments the United States Antineoplastic Drugs market as:

United States Antineoplastic Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England

The Middle Atlantic

The Midwest

The West

The South

Southwest

United States Antineoplastic Drugs Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Chemotherapeutic Agents
Biological/Immunotherapeutic Agents
Personalized Medicine

United States Antineoplastic Drugs Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals
Clinics
Cancer Rehabilitation Centers
Ambulatory Surgical Centers

United States Antineoplastic Drugs Market: Players Segment Analysis (Company and Product introduction, Antineoplastic Drugs Sales Volume, Revenue, Price and Gross Margin):

Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Baxter Healthcare
Boehringer Ingelheim
Aspen Global
Bayer AG
Teva pharmaceutical Industries
Johnson & Johnson
Merc & Co.
Pfizer
Accord Healthcare
Genentech
Lundbeck
AbbVie

In a word, the report provides detailed statistics and analysis on the state of the

industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

- 1.1 Definition of Benign Prostatic Hyperplasia (BPH) Drugs in This Report
- 1.2 Commercial Types of Benign Prostatic Hyperplasia (BPH) Drugs
 - 1.2.1 Alpha-blocker
 - 1.2.2 Phosphodiesterase Type-5 Inhibitors
 - 1.2.3 5-alpha-Reductase Inhibitors
- 1.3 Downstream Application of Benign Prostatic Hyperplasia (BPH) Drugs
 - 1.3.1 Hospitals
 - 1.3.2 Clinics
 - 1.3.3 Others
- 1.4 Development History of Benign Prostatic Hyperplasia (BPH) Drugs
- 1.5 Market Status and Trend of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2023
 - 1.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2017
- 2.2 Production Market of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
 - 2.2.1 Production Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
 - 2.2.2 Production Value of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
- 2.3 Demand Market of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
- 2.4 Production and Demand Status of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
 - 2.4.1 Production and Demand Status of Benign Prostatic Hyperplasia (BPH) Drugs by Regions 2013-2017
 - 2.4.2 Import and Export Status of Benign Prostatic Hyperplasia (BPH) Drugs by Regions 2013-2017

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Production Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Types
- 3.2 Production Value of Benign Prostatic Hyperplasia (BPH) Drugs by Types
- 3.3 Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry

4.2 Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

5.1 Global Economy Situation and Trend Overview

5.2 Benign Prostatic Hyperplasia (BPH) Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

6.1 Production Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Major Manufacturers

6.2 Production Value of Benign Prostatic Hyperplasia (BPH) Drugs by Major Manufacturers

6.3 Basic Information of Benign Prostatic Hyperplasia (BPH) Drugs by Major Manufacturers

6.3.1 Headquarters Location and Established Time of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturer

6.3.2 Employees and Revenue Level of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturer

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Astellas Pharma

7.1.1 Company profile

- 7.1.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
- 7.1.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma
- 7.2 Eli Lilly
 - 7.2.1 Company profile
 - 7.2.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.3 GlaxoSmithKline
 - 7.3.1 Company profile
 - 7.3.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.3.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
- 7.4 Sanofi
 - 7.4.1 Company profile
 - 7.4.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Sanofi
- 7.5 ADC Therapeutics
 - 7.5.1 Company profile
 - 7.5.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.5.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of ADC Therapeutics
- 7.6 Bayer HealthCare
 - 7.6.1 Company profile
 - 7.6.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.6.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare
- 7.7 Bristol-Myers Squibb
 - 7.7.1 Company profile
 - 7.7.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.7.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
- 7.8 Valeant Pharmaceuticals
 - 7.8.1 Company profile
 - 7.8.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.8.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals
- 7.9 Endo Pharmaceuticals

- 7.9.1 Company profile
- 7.9.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
- 7.9.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals
- 7.10 Foresee Pharmaceuticals
 - 7.10.1 Company profile
 - 7.10.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.10.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Foresee Pharmaceuticals
- 7.11 Madrigal Pharmaceuticals
 - 7.11.1 Company profile
 - 7.11.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.11.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Madrigal Pharmaceuticals
- 7.12 Merck
 - 7.12.1 Company profile
 - 7.12.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.12.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Merck
- 7.13 Novartis
 - 7.13.1 Company profile
 - 7.13.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.13.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Novartis
- 7.14 Spectrum Pharmaceuticals
 - 7.14.1 Company profile
 - 7.14.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.14.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Spectrum Pharmaceuticals
- 7.15 Takeda Pharmaceuticals
 - 7.15.1 Company profile
 - 7.15.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.15.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
- 7.16 Teva
- 7.17 Advaxis
- 7.18 ANI Pharmaceuticals
- 7.19 BHR Pharma

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

- 8.1 Industry Chain of Benign Prostatic Hyperplasia (BPH) Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

- 9.1 Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
- 9.2 Raw Materials Cost Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
- 9.3 Labor Cost Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
- 9.4 Manufacturing Expenses Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Antineoplastic Drugs-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/AB9FF12E635MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AB9FF12E635MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970